Bristol-Myers Squibb Breaks Oral Hep C Treatment Barrier
By
Shirley Haley / Email the Author / “The Pink Sheet” DAILY Jan. 19, 2012
Word Count: 771 / Article # 14120119002
Executive Summary
The proof-of-concept news is based on the finding that four of 11 patients (36%) in the all-oral arm of an exploratory 21-patient trial achieved a sustained virologic response 12 weeks after completion of treatment, though in the other arm, which added peginterferon and ribavirin to the duo, all 10 patients reached that cure threshold.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.